IND-Ready Toxicology Decision Framework

A Non-GLP to GLP Toxicology Decision Framework for IND Readiness

Developing a successful Investigational New Drug (IND) submission requires a strategic and integrated approach to non-clinical safety assessment. While non-GLP and GLP toxicology studies are often viewed as separate stages, the most effective programs treat them as a continuous, interconnected process.

The IND-Ready Toxicology Decision Framework

Flowchart showing how non-GLP studies support IND-ready GLP toxicology through stages including early safety assessment, PK exposure, risk identification, species selection, dose justification, GLP study design, and development of a cohesive regulatory safety narrative.

This decision-tree framework demonstrates how early non-GLP insights directly inform IND-enabling GLP toxicology strategy. By starting with early signal detection, sponsors can identify potential safety concerns and refine candidate selection before progressing to more advanced studies. Pharmacokinetic (PK) exposure analysis then helps ensure that preclinical models reflect clinically relevant exposure levels.

As development advances, risk identification helps identify which organs or systems may be vulnerable. These insights guide critical decisions such as translational species selection and dose justification, ensuring that study parameters are both scientifically sound and regulatorily defensible.

With this foundation, the GLP study design can be aligned with the compound’s specific risk profile, including duration, endpoints, and cohort structure. This integrated approach enables the development of a cohesive IND-ready safety narrative, transforming individual data points into a unified, regulator-ready story.

Ready to Apply This to Your Program?

The framework is just the starting point. Translating non-GLP insights into an IND-ready toxicology strategy requires tailored expertise across study design, risk assessment, and regulatory expectations.

Request Toxicology Guidance